Psilocybin, the main psychedelic compound in magic mushrooms, made laboratory mice more accurate on a simple decision task but slower to commit to an answer, according to a new study from Boston University neuroscientists. The paper, published November 20 in the journal Science Advances, found that ketamine had a strikingly similar effect, even though the two drugs act on the brain through very different chemical pathways.
The research team was led by first author C. Delgado-Sallent, with Benjamin Scott and Steve Ramirez as senior investigators. Their goal was to answer a basic question that clinical trials have mostly skipped: what happens to the way a brain makes choices while a psychedelic is active?
The researchers trained mice on a task built to separate two decision styles. In one, an animal pays attention to what is in front of it. In the other, it falls back on habits. Each trial started when a mouse poked its nose into a center port. Lights then blinked at two side ports, and the side with the faster flashing held a sugary reward.
Mice that received no drug did reasonably well, but they made predictable mistakes. Some favored one side no matter what the lights showed. Others tended to go back to wherever they had last been rewarded.
Mice that received psilocybin or ketamine made fewer of those errors. According to the researchers, the treated animals relied less on habit and more on the light cues, and picked the rewarded port more often. They also took longer to decide.
"Both drugs strengthen the influence of sensory evidence on choices and reduce the effect of bias," Scott said in describing the work.
To understand the change, the team ran the animals' choices and reaction times through two kinds of behavioral models. Both pointed the same way. Under psilocybin or ketamine, mice seemed to require more evidence before acting, which the researchers describe as a higher decision threshold. The mice also spent more time in what the team calls a sensory-engaged state, and less in states driven by side preferences.
The group then mapped activity across the whole brain and found changes in networks tied to the task, especially the orbitofrontal cortex, a region involved in weighing options and outcomes. Imaging of neurons in that region showed their collective activity was reorganized under the drugs. The cells still responded to the task, but the timing and coordination of their firing shifted.
The authors say the results fit a popular theory in psychedelic science that these compounds loosen the brain's reliance on prior expectations and make it more responsive to new information.
Scott has emphasized that the improvement came at a price. Because accuracy rose while speed fell, he suggested the same effect could be a problem where reaction time matters, offering driving and sports as examples.
The study also has clear limits. It was done in mice performing a single, simple perceptual task while the drugs were active. It does not show that psilocybin improves human judgment, and it does not test any lasting effect. The researchers frame the work as a step toward explaining how psychedelics change cognition. They suggest that loosening habitual, repetitive patterns could be part of what interests clinicians about these compounds.
That question is drawing research attention well beyond Boston University. In the same city, the Massachusetts General Hospital Center for the Neuroscience of Psychedelics studies how these drugs act on the brain. Programs such as The Parsons Research Center for Psychedelic Healing at Mount Sinai and the Yale Program for Psychedelic Science / Connecticut Mental Health Center run human psilocybin research. Basic animal studies like this one help those groups decide which brain mechanisms to look for in people.